skin care, smoking lung cancer, skin disease, skin diseases, skin cancer, prostate cancer, testicle cancer, mouth cancer, oral cancer, oral cancer symptoms, causes of mouth cancer, prostate cancer early detection, prostrate cancer, prostate cancer symptoms, prostate cancer treatment, prostrate cancer symptoms, skin cancer melinoma, skin cancer prevention, skin cancer symptoms, small cell cancer, small cell lung cancer, symptoms bone cancer, symptoms cervical cancer, symptoms of lung cancer, testicular cancer, stomach cancer, stomach cancer symptoms, rectal cancer, squamous cell cancer, ovarian cancer, ovarian cancer symptoms, ovarian cancer treatment

mouthcancer

your most complete directory for cancer information and medications Check here

skin care, smoking lung cancer, skin disease, skin diseases, skin cancer, prostate cancer, testicle cancer, mouth cancer, oral cancer, oral cancer symptoms, causes of mouth cancer, prostate cancer early detection, prostrate cancer, prostate cancer symptoms, prostate cancer treatment, prostrate cancer symptoms, skin cancer melinoma, skin cancer prevention, skin cancer symptoms, small cell cancer, small cell lung cancer, symptoms bone cancer, symptoms cervical cancer, symptoms of lung cancer, testicular cancer, stomach cancer, stomach cancer symptoms, rectal cancer, squamous cell cancer, ovarian cancer, ovarian cancer symptoms, ovarian cancer treatment

In January 1997, 62 subjects who had been the mouthcancer placebos in the 1995 study were invited to receive the vitamin B12. In June 1997, the 62 placebo subjects were sent a questionnaire asking: How would you compare your overall allergy (hay fever) symptoms this spring to the last two springs? 20 people responded, with 15 reporting having had the B12 treatment, and 5 not. 12 of the 15 reported at least a slight improvement in overall allergy symptoms, and 1 of the 5. Improvement ratios - 12:3 having received treatment, 1:4 not having received treatment.8 A bioequivalence study showed that a 3000 mcg lozenge delivered an equivalent amount of cyanocobalamin to the blood as a 15 mcg injection.9 From the spring to the summer patients with demonstrated allergic rhinitis received with the cyanocobalamin (or placebo) containing lozenge twice daily for 21 consecutive days. All subjects also received C and B oral multivitamins for 21 days. Twice daily mouthcancer subjects maintained a nine-week diary on sneezing, runny nose, nasal congestion, itchy eyes, itchy nose and antihistamine (chlorpheniramine) use. In the post-treatment period, the active group (n=15) recorded on average a greater reduction in symptoms and in antihistamine use than the placebo group (n=9). The results yielded reductions (0.1>p>0.01) in total weekly symptom/rescue medication for the active group compared to the placebo for weeks 2, 6, 8 and 9. The mouthcancer results tend to replicate those of the studies on injectable cyanocobalamin.10

In January 1997, 62 subjects who had been the mouthcancer placebos in the 1995 study were invited to receive the vitamin B12. In June 1997, the 62 placebo subjects were sent a questionnaire asking: How would you compare your overall allergy (hay fever) symptoms this spring to the last two springs? 20 people responded, with 15 reporting having had the B12 treatment, and 5 not. 12 of the 15 reported at least a slight improvement in overall allergy symptoms, and 1 of the 5. Improvement ratios - 12:3 having received treatment, 1:4 not having received treatment.8 A bioequivalence study showed that a 3000 mcg lozenge delivered an equivalent amount of cyanocobalamin to the blood as a 15 mcg injection.9 From the spring to the summer patients with demonstrated allergic rhinitis received with the cyanocobalamin (or placebo) containing lozenge twice daily for 21 consecutive days. All subjects also received C and B oral multivitamins for 21 days. Twice daily mouthcancer subjects maintained a nine-week diary on sneezing, runny nose, nasal congestion, itchy eyes, itchy nose and antihistamine (chlorpheniramine) use. In the post-treatment period, the active group (n=15) recorded on average a greater reduction in symptoms and in antihistamine use than the placebo group (n=9). The results yielded reductions (0.1>p>0.01) in total weekly symptom/rescue medication for the active group compared to the placebo for weeks 2, 6, 8 and 9. The mouthcancer results tend to replicate those of the studies on injectable cyanocobalamin.10

Check here - your most complete directory for cancer information and medications

mouthcancer

skin care, smoking lung cancer, skin disease, skin diseases, skin cancer, prostate cancer, testicle cancer, mouth cancer, oral cancer, oral cancer symptoms, causes of mouth cancer, prostate cancer early detection, prostrate cancer, prostate cancer symptoms, prostate cancer treatment, prostrate cancer symptoms, skin cancer melinoma, skin cancer prevention, skin cancer symptoms, small cell cancer, small cell lung cancer, symptoms bone cancer, symptoms cervical cancer, symptoms of lung cancer, testicular cancer, stomach cancer, stomach cancer symptoms, rectal cancer, squamous cell cancer, ovarian cancer, ovarian cancer symptoms, ovarian cancer treatment

oral cancer symptomsoral canceroralcanceroralcancersymptoms
ovarian cancer symptomsovarian cancer treatmentovarian cancerovariancancer

hostmaster@cancer-site.com

2003 cancer-site.com.

All Rights Reserved. The products mentioned are trademarks of their respective owners and are not owned by us. Read our privacy guidelines.